Fred Hutchinson Cancer Center, Seattle, Washington.
Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Clin Cancer Res. 2022 Jun 1;28(11):2206-2208. doi: 10.1158/1078-0432.CCR-22-0335.
Continuation of programmed cell death protein 1 (PD-1) inhibitors in combination with chemotherapy did not improve clinical outcomes for patients with non-small cell lung cancer who progressed on prior PD-1/programmed death ligand 1 inhibitor monotherapy. This highlights the need to evaluate the precise mechanisms of resistance to PD-1 axis inhibitors and explore alternative therapeutic strategies to overcome resistance. See related article by Jung et al., p. 2321.
程序性细胞死亡蛋白 1（PD-1）抑制剂联合化疗在先前接受 PD-1/程序性死亡配体 1 抑制剂单药治疗后进展的非小细胞肺癌患者中并未改善临床结局。这凸显了评估 PD-1 轴抑制剂耐药的确切机制以及探索克服耐药的替代治疗策略的必要性。详见 Jung 等人的相关文章，第 2321 页。
